An isolated polypeptide and uses thereof

By designing peptides that specifically bind to the c-Myc protein, the interaction between RALY and c-Myc is interfered with, promoting the degradation of the c-Myc protein. This solves the problems of drug resistance and side effects in the treatment of advanced cancer and achieves a highly effective anti-cancer effect.

CN122255242APending Publication Date: 2026-06-23INST OF HEALTH & MEDICINE HEFEI COMPREHENSIVE NAT SCI CENT +1
View PDF 7 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
INST OF HEALTH & MEDICINE HEFEI COMPREHENSIVE NAT SCI CENT
Filing Date
2025-07-08
Publication Date
2026-06-23

AI Technical Summary

Technical Problem

The effectiveness of existing anti-cancer treatments for advanced cancer still needs to be improved, especially for tumor cells with abnormally high c-Myc expression, where traditional methods suffer from drug resistance and side effects.

Method used

Develop an isolated peptide that specifically binds to c-Myc protein and promotes its degradation via the ubiquitin-proteasome pathway, thereby inhibiting cancer cell proliferation. Interference with the full-length RALY protein's interaction with c-Myc can be achieved by designing key binding fragments of the RALY protein (such as amino acids 116–128).

Benefits of technology

It significantly inhibits cancer cell growth, reduces cancer cell survival, decreases side effects, and improves treatment efficacy, exhibiting good biocompatibility and targeted delivery potential.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005488726270000061
    Figure BDA0005488726270000061
  • Figure BDA0005488726270000071
    Figure BDA0005488726270000071
  • Figure HDA0005488726280000011
    Figure HDA0005488726280000011
Patent Text Reader

Abstract

The application provides an isolated polypeptide and application thereof, and the polypeptide comprises an amino acid sequence shown in SEQ ID NO: 2 or an amino acid sequence with at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity with the amino acid sequence shown in SEQ ID NO: 2. The isolated polypeptide can specifically bind to a c-Myc protein, destroy the stabilizing effect of RALY on the c-Myc protein, promote the degradation of the c-Myc protein through a ubiquitin-proteasome pathway, inhibit the proliferation of cancer cells, reduce the survival ability of the cancer cells, and can effectively prevent and / or treat tumors.
Need to check novelty before this filing date? Find Prior Art